Cempra to Present at J.P. Morgan Healthcare Conference
January 04, 2017 07:00 ET
|
Cempra, Inc.
CHAPEL HILL, N.C., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra Receives Complete Response Letter From FDA For Solithromycin NDAs
December 29, 2016 06:55 ET
|
Cempra, Inc.
CHAPEL HILL, N.C., Dec. 29, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Cempra, Inc. - CEMP
December 27, 2016 14:52 ET
|
The Rosen Law Firm PA
NEW YORK, Dec. 27, 2016 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Cempra, Inc. securities...
Cempra Appoints Dr. David Zaccardelli as Acting Chief Executive Officer, Promotes Chief Commercial Officer David Moore to President
December 12, 2016 09:01 ET
|
Cempra, Inc.
—Leadership changes bolster manufacturing, regulatory and commercial expertise— —Cempra founder, president and CEO, Dr. Prabhavathi Fernandes, announces retirement from the company and...
Scott+Scott, Attorneys at Law, LLP Reminds Investors of Upcoming Deadline to File Lead Plaintiff Papers in Cempra, Inc. (NASDAQ: CEMP) Securities Case
December 05, 2016 13:35 ET
|
Scott + Scott, Attorneys at Law, LLP
NEW YORK, Dec. 05, 2016 (GLOBE NEWSWIRE) -- Scott+Scott, Attorneys at Law, LLP (“Scott+Scott”), a national investor rights law firm, reminds investors that January 3, 2017 is the last day to file...
Toyama Chemical (a Subsidiary of FUJIFILM Holdings Corporation) Begins Phase 3 Studies in Japan With Cempra’s Solithromycin
December 05, 2016 08:00 ET
|
Cempra, Inc.
CHAPEL HILL, N.C., Dec. 05, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Scott+Scott, Attorneys at Law, LLP Reminds Investors of Upcoming Deadline to File Lead Plaintiff Papers in Cempra, Inc. (NASDAQ: CEMP) Securities Case
November 14, 2016 11:36 ET
|
Scott + Scott, Attorneys at Law, LLP
NEW YORK, Nov. 14, 2016 (GLOBE NEWSWIRE) -- Scott+Scott, Attorneys at Law, LLP (“Scott+Scott”), a national investor rights law firm, reminds investors that January 3, 2017 is the last day to file...
Cempra to Present at Two Upcoming Investor Conferences
November 09, 2016 07:30 ET
|
Cempra, Inc.
CHAPEL HILL, N.C., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
FDA Advisory Committee Votes That Efficacy Results of Cempra’s Solithromycin Outweigh Risks for Community-Acquired Bacterial Pneumonia
November 04, 2016 22:40 ET
|
Cempra, Inc.
—FDA PDUFA dates December 27 & 28, 2016— CHAPEL HILL, N.C., Nov. 04, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing...
Cempra Stock Trading Halted Today; FDA Advisory Committee to Discuss Solithromycin
November 04, 2016 07:05 ET
|
Cempra, Inc.
CHAPEL HILL, N.C., Nov. 04, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...